Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. Br J Cancer. 2006 Dec 18;95(12):1626-31
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer.Br J Cancer. 2005 Nov 28;93(11):1215-21.
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study JCO May 1 2005: 23 2988-2995.
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer. 2003;89:1837-42.
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83.